.svg)
Highlighted Event
Results for the First Quarter 2024
Sales ended at MNOK 133.8, 3.5% above the first quarter last year (MNOK 129.3). Currency neutral sales of own products was down 1%. Recurring sales remain high at 75% or MNOK 83.5 (68% or MNOK 73.8) for the quarter.
Presentation of Medistim Q1 2024 Financial Results
Apr 3, 2024
Medistim ASA invites you to the presentation of the financial results for the first quarter 2024
Results for the Fourth Quarter 2023
Feb 29, 2024
Currency neutral sales of own products was down 17.4 % for the quarter and down 5.1 % for the year. Download the full report and presentation, and watch the video recording from the webinar below.…
Medistim is opening a direct sales office in Sweden
Oct 31, 2023
This move is part of the company's ongoing commitment to providing exceptional service to customers as well as fulfilling the company’s global growth strategy. The company is well positioned to continue its growth by further…
Results for the Third Quarter 2023
Oct 27, 2023
Currency neutral sales of own products was down 5.6% for the quarter and up 1.2% YTD September. Operating profit (EBIT) for the quarter ended at MNOK 34 giving a 27.0% EBIT margin (MNOK 34, a…
Results for the Second Quarter and First Half 2023
Aug 31, 2023
Currency-neutral sales of own products were up 4.0% for the quarter and 2.5% for the first half. Operating profit (EBIT) for the quarter is up 13.1% and ended at MNOK 42.2, an EBIT margin of…
Medistim announces partnership with ROMA-Women Trial
Jun 5, 2023
Medistim is pleased to announce its partnership with ROMA-Women, a groundbreaking cardiac surgery trial that is specifically focused on women. Historically, cardiovascular research and treatment protocols have primarily focused on men, leaving women underrepresented in…
